Related Experiment Video
Updated: Jan 16, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
eHealth Applications Improve Glycemic Control in Patients With Diabetes: Randomized Controlled Trial
Junjie Huang1,2, Claire Chenwen Zhong1,2, Siu Hin Wong1,2
1The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
JMIR Formative Research
|September 26, 2025
Summary
An eHealth chronic disease management module improved glycemic control in patients with suboptimal levels. Adherence to the app is crucial for sustained benefits in managing diabetes.
Area of Science:
- Digital Health
- Clinical Research
- Chronic Disease Management
Background:
- An eHealth app introduced a chronic disease management module to improve clinical consultations and self-health management.
- Limited data existed on health outcomes following the module's use.
Purpose of the Study:
- To evaluate the health outcomes of individuals using an individualized electronic application's health management module compared to a control group.
- To assess the impact of the eHealth chronic disease management module on clinical outcomes.
Main Methods:
- A randomized controlled trial involved 165 participants (82 control, 83 intervention).
- Clinical outcomes including blood pressure, hemoglobin A1c (HbA1c), and renal function were monitored over 4 and 8 months.
- Student t tests and chi-square tests analyzed group differences.
Main Results:
- After 4 months, the intervention group showed significantly better glycemic control (mean HbA1c 6.76% vs. 7.09%, P=.007).
- More intervention participants achieved optimal HbA1c levels (73.4% vs. 49.3%, P=.004).
- App usage decreased from month 4 to month 8 (P<.001), highlighting adherence as key for sustained control.
Conclusions:
- The eHealth module shows potential for clinical use in patients with suboptimal glycemic control.
- Participant compliance with the module is essential for long-term benefits.
Keywords:
diabeteseHealth chronic disease management moduleglycemic controlhemoglobin A1crandomized controlled trialMore Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
717
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.6K
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:06Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
01:23Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525